Home/Filings/4/0001140361-21-037653
4//SEC Filing

Lundbeckfond Invest A/S 4

Accession 0001140361-21-037653

CIK 0001865494other

Filed

Nov 11, 7:00 PM ET

Accepted

Nov 12, 4:15 PM ET

Size

11.9 KB

Accession

0001140361-21-037653

Insider Transaction Report

Form 4
Period: 2021-11-09
Transactions
  • Conversion

    Series B Preferred Stock

    2021-11-09219,5950 total
    Common Stock (2,014,161 underlying)
  • Purchase

    Common Stock

    2021-11-09$14.00/sh+2,142,857$29,999,9986,049,452 total
  • Conversion

    Series C Preferred Stock

    2021-11-09150,5340 total
    Common Stock (1,892,434 underlying)
  • Conversion

    Common Stock

    2021-11-09+2,014,1612,014,161 total
  • Conversion

    Common Stock

    2021-11-09+1,892,4343,906,595 total
Footnotes (2)
  • [F1]Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series B Preferred Stock had no expiration date.
  • [F2]Upon the closing of the IPO, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date.

Issuer

IO Biotech, Inc.

CIK 0001865494

Entity typeother
IncorporatedDenmark

Related Parties

1
  • filerCIK 0001591046

Filing Metadata

Form type
4
Filed
Nov 11, 7:00 PM ET
Accepted
Nov 12, 4:15 PM ET
Size
11.9 KB